Home › Autoimmune Diseases › Minnesota
Autoimmune Diseases clinical trials in Minnesota
9 studies for Autoimmune Diseases are looking for participants at sites in Minnesota.
Cities in Minnesota
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- Mayo Clinic - Accepting Adult Patients, Rochester
RecruitingPhase 2/3
Ages 6 to 75 · All sexes · Updated Nov 13, 2026 · NCT06154252Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
- Mayo Clinic: Division of Rheumatology, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07103746Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- National Marrow Donor Program, Minneapolis
RecruitingPhase 2Healthy volunteers welcome
Ages 4 to 75 · All sexes · Updated Nov 5, 2026 · NCT02579967Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases
- University of Minnesota Delaware Clinical Research Unit, Minneapolis
- Mayo Clinic, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT06626919RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- Mayo Clinic - Rochester, Rochester
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Oct 19, 2026 · NCT06359041RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Mayo Clinic Rochester, Rochester
RecruitingPhase 2/3
Ages 18 to 75 · All sexes · Updated Oct 16, 2026 · NCT06328777RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- University of Minnesota, Minneapolis
RecruitingPhase 1/2
Ages 12 to 65 · All sexes · Updated Oct 6, 2026 · NCT06121297Abatacept for the Treatment of Giant Cell Arteritis
- Mayo Clinic, Rochester
RecruitingPhase 3
Ages 50 and older · All sexes · Updated Aug 20, 2026 · NCT04474847A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- University of Minnesota Medical School, Minneapolis
RecruitingPhase 1
Ages 12 to 70 · All sexes · Updated May 22, 2026 · NCT06308978From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.